The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the continued support of the Collaborative Network for Clinical Research on Immune Tolerance. The purpose of this program is to enhance understanding of the underlying mechanisms of the induction, maintenance, and loss of immune tolerance in humans; and to develop improved tolerogenic interventions for the prevention and treatment of immune system mediated diseases (including transplant rejection, autoimmune diseases, and asthma and allergic diseases). The three major scientific goals include: 1) conduct clinical trials to determine the safety and efficacy of promising tolerogenic strategies in liver, kidney and pancreatic islet transplantation; allergic diseases and asthma; and autoimmune diseases; 2) investigate the basic mechanisms of immune tolerance in these diseases as an integral part of clinical trials; and 3) develop, refine and validate immune assays to monitor the induction, maintenance, and loss of tolerance in these disorders. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Nonprofit

• Nonprofits non-higher education without 501(c)(3)
• Nonprofits non-higher education with 501(c)(3)
• Other Native American tribal organizations

Education

• Public and state institutions of higher education
• Private institutions of higher education
• Independent school districts

Government

• City or township governments
• State governments
• County governments
• Public and Indian housing authorities
• Special district governments
• Federally recognized Native American tribal governments

Business

• For-profit organizations other than small businesses
• Small businesses

Miscellaneous

• Other